Technical Analysis for NNVC - NanoViricides, Inc.

Grade Last Price % Change Price Change
grade F 0.26 0.00% 0.00
NNVC closed unchanged on Friday, January 18, 2019, on 62 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical NNVC trend table...

Date Alert Name Type % Chg
Jan 18 Crossed Above 20 DMA Bullish 0.00%
Jan 18 Wide Bands Range Expansion 0.00%
Jan 17 20 DMA Resistance Bearish 0.00%
Jan 17 Doji - Bullish? Reversal 0.00%
Jan 17 Wide Bands Range Expansion 0.00%
Jan 16 20 DMA Resistance Bearish -1.85%
Jan 16 Inside Day Range Contraction -1.85%
Jan 16 Wide Bands Range Expansion -1.85%
Jan 15 Fell Below 20 DMA Bearish 0.00%
Jan 15 Wide Bands Range Expansion 0.00%

Older signals for NNVC ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
NanoViricides, Inc. a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at advanced pre-clinical stage, which include two FluCide drugs comprising NV-INF-2, an oral anti-influenza drug and NV-INF-1, a injectable anti-influenza drug for novel strain of H7N9, Bird Flu H5N1, and other Highly Pathogenic Influenzas; HIVCide, an anti-human immunodeficiency virus (HIV) drug candidate that could enable a functional cure for HIV/AIDS; HerpeCide, a skin cream or gel formulation for the treatment of oral and genital herpes lesions; Nanoviricide anti-viral eye drops against external eye viral infections; and DengueCide, a treatment against Dengue viruses. It is also developing RabiCide, an anti-rabies nanoviricide; and Nanoviricide for the treatment of various strains of Ebola and Marburg filoviruses. The company has licenses to develop drugs for the treatment of human viral diseases, such as H5N1 (avian flu), human influenza, human immunodeficiency virus (HIV/AIDS), hepatitis B virus, hepatitis C virus, herpes simplex virus, and rabies; and dengue viruses, Japanese encephalitis virus, West Nile virus, viruses causing viral conjunctivitis and ocular herpes, and Ebola/Marburg viruses, as well as viral diseases of the eye comprising epidemic kerato-conjunctivitis and herpes keratitis. NanoViricides, Inc. was founded in 2005 and is based in West Haven, Connecticut.
Is NNVC a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 1.06
52 Week Low 0.2
Average Volume 103,957
200-Day Moving Average 0.4243
50-Day Moving Average 0.3088
20-Day Moving Average 0.2599
10-Day Moving Average 0.271
Average True Range 0.0372
ADX 21.96
+DI 10.3528
-DI 14.7677
Chandelier Exit (Long, 3 ATRs ) 0.2184
Chandelier Exit (Short, 3 ATRs ) 0.3116
Upper Bollinger Band 0.3185
Lower Bollinger Band 0.2013
Percent B (%b) 0.5
BandWidth 45.094267
MACD Line -0.0109
MACD Signal Line -0.0137
MACD Histogram 0.0028
Fundamentals Value
Market Cap 16.46 Million
Num Shares 63.3 Million
EPS -0.17
Price-to-Earnings (P/E) Ratio -1.53
Price-to-Sales 0.00
Price-to-Book 3.04
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.29
Resistance 3 (R3) 0.29 0.29 0.29
Resistance 2 (R2) 0.29 0.28 0.29 0.28
Resistance 1 (R1) 0.27 0.27 0.27 0.27 0.28
Pivot Point 0.27 0.27 0.27 0.27 0.27
Support 1 (S1) 0.25 0.26 0.25 0.25 0.24
Support 2 (S2) 0.25 0.25 0.25 0.24
Support 3 (S3) 0.23 0.25 0.24
Support 4 (S4) 0.23